Takeda Pharmaceutical Co ADR (TAK) is overvalued and we do not publish a verdict for Viatris Inc (VTRS).
We publish an intrinsic value for TAK but not for VTRS, so the two cannot be ranked on price.
Values as of the 22 Sept 2026 close.
Discounting its cash flows at 8.6% (average of 2 methods) values the shares at $10.20; the price of $18.95 is 86% above that value, and 77% of that value comes from beyond year five.
Leak Score 0/100 on 2 of 12 signals
We do not publish a value for this company: not even its current assets cover what it owes.
Leak Score 39/100 on 7 of 12 signals
| Metric | TAK | VTRS |
|---|---|---|
| Verdict | Overvalued | Not valued |
| Price | $18.95 | $17.18 |
| Intrinsic value | $10.20 | — |
| Margin of safety | -86% | — |
| Leak Score | 0/100 (2/12) | 39/100 (7/12) |
| Market cap | $60.3B | $19.7B |
| Revenue growth, 5 years | -0.2% | 3.7% |
| Operating margin | 15.3% | 9.7% |
| Net margin | -3.5% | -2.8% |
| Return on equity | -2.2% | -2.8% |
| Debt to equity | 0.65 | 0.96 |
| Forward P/E | 30.2x | 6.4x |
| P/B | 1.3x | 1.4x |
| Dividend yield | 3.4% | 3.0% |